Why the study?
Does preventive low-dose aspirin therapy provide a net benefit in women at risk for or with established cardiovascular disease?
Does preventive low-dose aspirin therapy provide a net benefit in women at risk for or with established cardiovascular disease?
Low-dose aspirin therapy is recommended for specific groups of women at elevated risk for cardiovascular events, including those ≥65 years, those with established CVD, or those with a 10-year CVD risk ≥10%.
Supports aspirin initiation in eligible high-risk women; reinforces Level 1 guideline recommendations for targeted CVD prevention.
Women age 65 and older without known cardiovascular disease (CVD), women of any age with established CVD, and women of any age with an estimated 10-year risk of CVD ≥10%, are likely to experience a net benefit from preventive low-dose aspirin therapy and should be considered for such therapy unless contraindicated.
No takes yet. Share an insight, caveat, or question.
Manson et al. (2013) studied this question. Preventive low-dose aspirin therapy provides a likely net benefit for women aged ≥65 years without CVD, women with established CVD, and women with an estimated 10-year CVD risk of ≥10%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: